
Please try another search
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich’s ataxia; and GBA1 gene replacement program to treat parkinson’s disease. In addition, it provides research program for the treatment of Huntington’s disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Michael J. Higgins | 62 | 2015 | Independent Chairman of the Board |
Alfred W. Sandrock | 66 | 2022 | President, CEO & Director |
Steven E. Hyman | 73 | 2015 | Independent Director |
James Arthur Geraghty | 71 | 2014 | Independent Director |
Glenn F. Pierce | 69 | 2017 | Independent Director |
Nancy Vitale | 54 | 2020 | Independent Director |
Catherine J. Mackey | 70 | 2022 | Independent Director |
Grace E. Colon | 57 | 2023 | Independent Director |
Jude Onyia | 61 | 2023 | Director |
George A. Scangos | 77 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review